Publication | Open Access

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer

Advanced/metastatic CancerPharmacokinetic EvaluationMedicinePharmacologyPharmacotherapyAnti-cancer AgentCancer TreatmentOncologyPhase Ib Safety